CONTEXT: Report of the summit held in April 2021 by the Centre for Medical Cannabis on the future of medical cannabis in Britain. The report includes reference to a growing body of real-world evidence, but also notes the evidence is patient reported rather than clinician | UK only data.
IMPACT: Low
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 6
1. “The National Institute of Health and Care Excellence (NICE) appraises the clinical evidence and cost effectiveness of medicines in the UK.”
2. “Medical cannabis has been lauded as an industry-creating, health-changing, and socially progressive medicine, but the UK has had anything but a smooth transition of medical cannabis from experimental agent to licensed medicine.”
3. “Understanding how this group of medicines has developed in the UK is key to understanding where they are heading, and most importantly how best to foster productive interventions for the medical cannabis industry, the clinical space, and above all the benefit of patient care.”
4. “On Thursday 15 April 2021, for the first time, the Centre for Medicinal Cannabis brought together leading clinical experts, institutional leaders such as NICE and the National Institute of Health Research, patient groups, healthcare professionals, condition charities, industry leaders and some of the most senior policymakers.”
5. “Attendees at this industry-first event, titled UK Medicinal Cannabis Summit: Evidence, Policy and Regulation, were able to discuss and shape the future of medical cannabis in Britain.”
Source URL: https://www.healtheuropa.eu/evidence-policy-and-regulation-in-medical-cannabis/108321/